Faron Pharmaceuticals Partners with MEDSIR and Vall d'Hebron for Sarcoma Immunotherapy Trial
I'm PortAI, I can summarize articles.
Faron Pharmaceuticals Oyj has partnered with MEDSIR and Vall d’Hebron to initiate a clinical trial, BEXAR, which will evaluate the combination of bexmarilimab and doxorubicin in patients with metastatic soft-tissue sarcoma. This collaboration aims to enhance treatment options for this aggressive cancer type, utilizing Faron’s immunotherapy expertise alongside the clinical leadership of MEDSIR and Vall d’Hebron. This marks a significant expansion of Faron’s research into solid tumors.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments